Future Directions: Evolving Role of Nonfactor Replacement Therapies

Learn about the latest data on nonfactor replacement therapies and their evolving role in the management of hemophilia A in by downloading this slideset.
Miguel A. Escobar, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.94 MB
Released: December 4, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Genentech, a member of the Roche Group
Sanofi Genzyme Corporation
Takeda Pharmaceutical Company Ltd

Related Content

Prof. Paul Coppo shares his thoughts on the current management of aTTP using clinical guidelines, biomarkers, and targeted therapies, from Clinical Care Options (CCO)

person default Paul Coppo, MD, PhD Released: October 21, 2021

Expert commentary on current and emerging treatment options for hemophilia A, from Clinical Care Options (CCO)

Miguel A. Escobar, MD
Program Director
Released: October 14, 2021

Clinical Care Options (CCO) expert faculty Guy Young, MD, on the evolution of prophylaxis therapy for hemophilia A and adherence challenges with young adult patients

Guy A. Young, MD Released: September 22, 2021

Clinical commentary from European hematology experts on key clinical trials presented at the virtual EHA 2021 meeting, from Clinical Care Options (CCO)

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci María-Victoria Mateos, MD, PhD Lydia Scarfò, MD Ali T. Taher, MD, PhD, FRCP Released: July 28, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue